{
  "id": 20902923,
  "title": "Massive hope for pancreatic cancer pill after trial saw tumours vanish",
  "url": "https://urgent.news/2026/11/20/massive-hope-for-pancreatic-cancer-pill-after-trial-saw-tumours-vanish-20902923",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-20T13:38:38.000Z",
  "source": {
    "name": "GBC Ghana",
    "slug": "gbc-ghana",
    "url": "https://www.gbcghanaonline.com/world/massive-hope-for-pancreatic-cancer-pill-after-trial-saw-tumours-vanish/2026/"
  },
  "original_language": "en",
  "account": "Experts are hailing a new pill as the most significant advancement in pancreatic cancer treatment in years – a daily medication that appears to shrink or even eliminate tumors in certain patients with one of the deadliest and toughest-to-treat cancers. In early medical trials, cancer became undetectable on scans in about 1 in 12 patients who received the drug, daraxonrasib, in combination with chemotherapy. Tumors stopped growing in nearly all of the 61 participants who had recently been diagnosed with advanced, metastatic pancreatic cancer. However, doctors caution that it's unclear how long the disease might remain in check and that it should not be considered a cure. Cancer Research UK called the results \"the biggest leap forward in decades\" for pancreatic cancer patients, with Dr. Sam Godfrey calling the findings \"incredibly exciting.\" Pancreatic cancer is notoriously difficult to treat and has the lowest survival rate among common cancers in the UK. Although chemotherapy can shrink tumors somewhat, the disease often returns. Most patients with advanced disease survive only months, not years. The trial followed patients for an average of 1.5 years, with most not experiencing a recurrence during this time. Longer studies are needed to determine if any of these cancers could be put into remission and for how long. The phase I/II trial showed that tumors stopped growing in 90% of patients, and 8% of patients (one in 12) saw their tumors disappear completely on CT scans. The drug, daraxonrasib, is a KRAS inhibitor that has already been approved in the US. It works by locking onto and shutting off specific mutations, called RAS, found in most pancreatic cancers that drive tumor growth. The treatment might also benefit other cancers with similar mutations. Experts hope that the early success seen in pancreatic cancer could be applied to other types of cancer as well. However, they stress that longer trials and more results are necessary to confirm the drug's long-term effectiveness and potential impact on overall survival.",
  "summary": "Experts are calling it the biggest breakthrough in pancreatic cancer treatment for decades – a daily pill that appears to shrink and possibly even eliminate tumours in some patients with one of the deadliest and hardest-to-treat cancers. Cancer became undetectable on scans in one in 12 of the patients given daraxonrasib along with chemotherapy in […]",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "BBC News",
        "title": "Massive hope for pancreatic cancer pill after trial saw tumours vanish",
        "url": "https://urgent.news/2026/11/20/massive-hope-for-pancreatic-cancer-pill-after-trial-saw-tumours-vanish",
        "published": "2026-11-20T00:08:22.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}